Texting to Promote Mobility in Overweight/Obese Adults with Peripheral Arterial Disease. This study is being conducted at the University of Kansas School of Medicine in Wichita, KS.

This is a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded,
placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in
subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung
disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will
include about 314 patients at approximately 100 clinical trial centers. The treatment phase
of the study will last approximately 16 weeks. Patients who complete all required
assessments will also be eligible to enter an open-label, extension study (RIN-PH-202).

The purpose of this study is to identify genes that increase the risk of developing
vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results
of these studies will provide vasculitis researchers with insight into the causes of these
diseases and generate new ideas for diagnostic tests and therapies, and will be of great
interest to the larger communities of researchers investigating vasculitis and other
autoimmune, inflammatory, and vascular diseases.